Applied Therapeutics (APLT) Competitors $0.38 -0.06 (-13.23%) Closing price 04:00 PM EasternExtended Trading$0.40 +0.02 (+4.53%) As of 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock APLT vs. ATYR, TSVT, HRTX, AURA, RNAC, CADL, PROK, CDTX, LFCR, and CRVSShould you be buying Applied Therapeutics stock or one of its competitors? The main competitors of Applied Therapeutics include Atyr PHARMA (ATYR), 2seventy bio (TSVT), Heron Therapeutics (HRTX), Aura Biosciences (AURA), Cartesian Therapeutics (RNAC), Candel Therapeutics (CADL), ProKidney (PROK), Cidara Therapeutics (CDTX), Lifecore Biomedical (LFCR), and Corvus Pharmaceuticals (CRVS). These companies are all part of the "pharmaceutical products" industry. Applied Therapeutics vs. Atyr PHARMA 2seventy bio Heron Therapeutics Aura Biosciences Cartesian Therapeutics Candel Therapeutics ProKidney Cidara Therapeutics Lifecore Biomedical Corvus Pharmaceuticals Atyr PHARMA (NASDAQ:ATYR) and Applied Therapeutics (NASDAQ:APLT) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, risk, community ranking, analyst recommendations, dividends, media sentiment, institutional ownership and profitability. Does the media favor ATYR or APLT? In the previous week, Applied Therapeutics had 8 more articles in the media than Atyr PHARMA. MarketBeat recorded 18 mentions for Applied Therapeutics and 10 mentions for Atyr PHARMA. Atyr PHARMA's average media sentiment score of 0.81 beat Applied Therapeutics' score of 0.79 indicating that Atyr PHARMA is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Atyr PHARMA 5 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Applied Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts prefer ATYR or APLT? Atyr PHARMA currently has a consensus target price of $18.60, suggesting a potential upside of 396.00%. Applied Therapeutics has a consensus target price of $6.10, suggesting a potential upside of 1,514.18%. Given Applied Therapeutics' higher probable upside, analysts clearly believe Applied Therapeutics is more favorable than Atyr PHARMA.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Atyr PHARMA 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.14Applied Therapeutics 0 Sell rating(s) 3 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50 Does the MarketBeat Community favor ATYR or APLT? Applied Therapeutics received 66 more outperform votes than Atyr PHARMA when rated by MarketBeat users. However, 100.00% of users gave Atyr PHARMA an outperform vote while only 57.14% of users gave Applied Therapeutics an outperform vote. CompanyUnderperformOutperformAtyr PHARMAOutperform Votes14100.00% Underperform VotesNo VotesApplied TherapeuticsOutperform Votes8057.14% Underperform Votes6042.86% Which has preferable earnings & valuation, ATYR or APLT? Atyr PHARMA has higher earnings, but lower revenue than Applied Therapeutics. Atyr PHARMA is trading at a lower price-to-earnings ratio than Applied Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAtyr PHARMA$235K1,420.28-$50.39M-$0.81-4.63Applied Therapeutics$455K117.59-$119.76M-$0.43-0.88 Which has more risk and volatility, ATYR or APLT? Atyr PHARMA has a beta of 0.79, indicating that its share price is 21% less volatile than the S&P 500. Comparatively, Applied Therapeutics has a beta of 2, indicating that its share price is 100% more volatile than the S&P 500. Do institutionals & insiders have more ownership in ATYR or APLT? 61.7% of Atyr PHARMA shares are held by institutional investors. Comparatively, 98.3% of Applied Therapeutics shares are held by institutional investors. 3.7% of Atyr PHARMA shares are held by company insiders. Comparatively, 8.6% of Applied Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Is ATYR or APLT more profitable? Atyr PHARMA's return on equity of -79.44% beat Applied Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Atyr PHARMAN/A -79.44% -59.16% Applied Therapeutics N/A -260.75%-76.04% SummaryAtyr PHARMA and Applied Therapeutics tied by winning 9 of the 18 factors compared between the two stocks. Get Applied Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for APLT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart APLT vs. The Competition Export to ExcelMetricApplied TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$53.50M$6.52B$5.37B$8.38BDividend YieldN/A2.65%5.22%4.11%P/E Ratio-0.238.9226.8419.71Price / Sales117.59253.80392.34117.39Price / CashN/A65.8538.2534.62Price / Book-1.896.466.794.50Net Income-$119.76M$143.98M$3.23B$248.18M7 Day Performance-22.11%3.04%4.07%1.14%1 Month Performance13.62%7.44%12.52%15.20%1 Year Performance-91.09%-2.46%16.83%6.56% Applied Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)APLTApplied Therapeutics4.0295 of 5 stars$0.38-13.2%$6.10+1,514.2%-89.6%$53.50M$455,000.00-0.2330News CoverageAnalyst RevisionATYRAtyr PHARMA2.8144 of 5 stars$3.00-1.2%$18.60+521.0%N/A$266.57M$235,000.00-3.1953News CoveragePositive NewsAnalyst ForecastTSVT2seventy bio1.5274 of 5 stars$5.00flat$4.25-15.0%N/A$266.15M$37.86M-2.69440News CoverageHRTXHeron Therapeutics3.8615 of 5 stars$1.74+0.9%$5.50+217.0%-43.5%$264.70M$148.52M-9.64300AURAAura Biosciences2.4576 of 5 stars$5.20+6.1%$22.75+337.5%-16.5%$258.01MN/A-2.9750Earnings ReportInsider TradeGap UpRNACCartesian Therapeutics1.5333 of 5 stars$10.01+0.3%$42.50+324.6%-60.4%$256.39M$34.17M-0.1964News CoverageAnalyst RevisionCADLCandel Therapeutics2.0197 of 5 stars$5.05-5.4%$21.00+315.8%-50.7%$248.81M$120,000.00-2.9260PROKProKidney1.8089 of 5 stars$0.86+11.1%$5.00+483.4%-79.6%$248.79M$76,000.00-1.553CDTXCidara Therapeutics4.472 of 5 stars$19.56+1.3%$39.57+102.3%+138.9%$246.44M$1.28M-0.7790LFCRLifecore Biomedical1.2466 of 5 stars$6.54-2.0%$8.00+22.4%+11.7%$241.96M$130.31M-11.67690Analyst ForecastCRVSCorvus Pharmaceuticals2.4031 of 5 stars$3.50-3.3%$16.33+366.7%+61.4%$239.96MN/A-3.7830Analyst Forecast Related Companies and Tools Related Companies Atyr PHARMA Alternatives 2seventy bio Alternatives Heron Therapeutics Alternatives Aura Biosciences Alternatives Cartesian Therapeutics Alternatives Candel Therapeutics Alternatives ProKidney Alternatives Cidara Therapeutics Alternatives Lifecore Biomedical Alternatives Corvus Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:APLT) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Applied Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Applied Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
